Current Medicines

For more than 140 years, we have been working tirelessly to develop and deliver medicines that meet real needs.

UK laws and regulations limit the amount of product information that we can provide to the public on our website. The product information on this website is intended for UK residents over the age of eighteen years only.


Abasaglar® (insulin glargine) 

Adcirca® (tadalafil) **

Alimta® (pemetrexed)

Cialis® (tadalafil)

Cymbalta® (duloxetine)

Cyramza® (ramucirumab)

Emgality® ▼ (galcanezumab)

Forsteo® (teriparatide)

Humalog® (human insulin analogue)

Humatrope® (somatropin)

Humulin® (human insulin)

Jardiance® (empagliflozin) *

Lyumjev®▼ (insulin lispro)

Olumiant®▼ (baricitinib)

Retsevmo®▼ (selpercatinib)

Strattera® (atomoxetine) 

Taltz® (ixekizumab)

Trulicity® (dulaglutide)

Verzenios®▼ (abemaciclib)

Yentreve® (duloxetine)

Zypadhera® (olanzapine pamoate monohydrate)

Zyprexa® (olanzapine)

To view Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit:

For England, Scotland, Wales:
For Northern Ireland and Ireland:

Report an Adverse Event or Product Complaint

If you experience side effects taking a Lilly medicine, talk to your doctor or other healthcare professional. This includes any possible side effects not listed in the package leaflet. By reporting side effects, you can help provide information on the safety of medicines.

Please do not use this website to report side effects or complaints about a Lilly product.

To report a side effect or product complaint with a Lilly product please call Lilly UK.


Call 01256 315000

Please press 1 to speak to Medical Information

Reporting forms and further information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store.

The following Lilly medicines are subject to additional monitoring: Emgality®▼, Lyumjev®▼, Olumiant®▼, Retsevmo®▼, and Verzenios®▼. This will allow faster identification of new safety information. You can help by reporting any side effects you may get to allow quick identification of new safety information.

* Lilly is not the marketing authorisation holder (MAH) but either promotes, markets or distributes this product

**Lilly is the marketing authorisation holder (MAH) but does not promote this product